Top

Published in:

01-05-2015 | Research Article

The prognostic nutritional index (PNI) predicts overall survival of small-cell lung cancer patients

Authors: Shaodong Hong, Ting Zhou, Wenfeng Fang, Cong Xue, Zhihuang Hu, Tao Qin, Yanna Tang, Yue Chen, Yuxiang Ma, Yunpeng Yang, Xue Hou, Yan Huang, Hongyun Zhao, Yuanyuan Zhao, Li Zhang

Published in: Tumor Biology | Issue 5/2015

Abstract

Recent studies have shown the prognostic nutritional index (PNI) had prognostic value in some solid tumors. However, no studies have examined its prognostic role in small-cell lung cancer (SCLC) patients. In this retrospective study, 724 consecutive SCLC patients were included between 2006 and 2013. Demographic, clinical, and laboratory data were collected. The PNI was calculated as 10 × serum albumin value (g/dl) + 0.005 × peripheral lymphocyte count (per mm³). Univariate and multivariate analyses were performed to assess the prognostic value of relevant factors. The optimal cut-off value of PNI for OS stratification was determined to be 52.48. A total of 464 and 260 patients were assigned to low and high PNI groups, respectively. Compared with low PNI, high PNI was associated with older age, advanced stage, and elevated lactate dehydrogenase (LDH). Median overall survival (OS) was worse in the low PNI group (low vs high, 15.90 vs 25.27 months; HR, 0.62; p < 0.001). In multivariate analysis, stage, performance status, LDH, and PNI were independent prognostic factors for OS. Subgroup analysis showed PNI was generally a significant prognostic factor in different clinical situations. The assessment of PNI could assist the identification of patients with poor prognosis and be a hierarchical factor in the future SCLC clinical trials.

Siegel R, Ma J, Zou Z, Jemal A. Cancer statistics, 2014. CA Cancer J Clin. 2014;64(1):9–29. doi:10.3322/caac.21208.CrossRefPubMed

Herbst RS, Heymach JV, Lippman SM. Lung cancer. N Engl J Med. 2008;359(13):1367–80. doi:10.1056/NEJMra0802714.CrossRefPubMed

Hayat MJ, Howlader N, Reichman ME, Edwards BK. Cancer statistics, trends, and multiple primary cancer analyses from the Surveillance, Epidemiology, and End Results (SEER) Program. Oncologist. 2007;12(1):20–37. doi:10.1634/theoncologist.12-1-20.CrossRefPubMed

Zatloukal P, Cardenal F, Szczesna A, Gorbunova V, Moiseyenko V, Zhang X, et al. A multicenter international randomized phase III study comparing cisplatin in combination with irinotecan or etoposide in previously untreated small-cell lung cancer patients with extensive disease. Ann Oncol. 2010;21(9):1810–6. doi:10.1093/annonc/mdq036.CrossRefPubMed

Kubota K, Hida T, Ishikura S, Mizusawa J, Nishio M, Kawahara M, et al. Etoposide and cisplatin versus irinotecan and cisplatin in patients with limited-stage small-cell lung cancer treated with etoposide and cisplatin plus concurrent accelerated hyperfractionated thoracic radiotherapy (JCOG0202): a randomised phase 3 study. Lancet Oncol. 2014;15(1):106–13. doi:10.1016/S1470-2045(13)70511-4.CrossRefPubMed

Jett JR, Schild SE, Kesler KA, Kalemkerian GP. Treatment of small cell lung cancer: diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest. 2013;143(5 Suppl):e400S–19. doi:10.1378/chest. 12-2363.CrossRefPubMed

F JB, Costa AF. Small cell lung cancer--state of the art and future perspectives. Rev Port Pneumol. 2007;13(4):587–604

Seifter EJ, Ihde DC. Therapy of small cell lung cancer: a perspective on two decades of clinical research. Semin Oncol. 1988;15(3):278–99.PubMed

Rawson NS, Peto J. An overview of prognostic factors in small cell lung cancer. A report from the Subcommittee for the Management of Lung Cancer of the United Kingdom Coordinating Committee on Cancer Research. Br J Cancer. 1990;61(4):597–604.CrossRefPubMedPubMedCentral

10.

Stokkel MP, van Eck-Smit BL, Zwinderman AH, Willems LN, Pauwels EK. Pretreatment serum lactate dehydrogenase as additional staging parameter in patients with small-cell lung carcinoma. J Cancer Res Clin Oncol. 1998;124(3–4):215–9.CrossRefPubMed

11.

Paesmans M, Sculier JP, Lecomte J, Thiriaux J, Libert P, Sergysels R, et al. Prognostic factors for patients with small cell lung carcinoma: analysis of a series of 763 patients included in 4 consecutive prospective trials with a minimum follow-up of 5 years. Cancer. 2000;89(3):523–33.CrossRefPubMed

12.

Jorgensen LG, Osterlind K, Genolla J, Gomm SA, Hernandez JR, Johnson PW, et al. Serum neuron-specific enolase (S-NSE) and the prognosis in small-cell lung cancer (SCLC): a combined multivariable analysis on data from nine centres. Br J Cancer. 1996;74(3):463–7.CrossRefPubMedPubMedCentral

13.

Yang X, Wang D, Yang Z, Qing Y, Zhang Z, Wang G, et al. CEA is an independent prognostic indicator that is associated with reduced survival and liver metastases in SCLC. Cell Biochem Biophys. 2011;59(2):113–9. doi:10.1007/s12013-010-9121-0.CrossRefPubMed

14.

Maestu I, Pastor M, Gomez-Codina J, Aparicio J, Oltra A, Herranz C, et al. Pretreatment prognostic factors for survival in small-cell lung cancer: a new prognostic index and validation of three known prognostic indices on 341 patients. Ann Oncol. 1997;8(6):547–53.CrossRefPubMed

15.

Laurie SA, Ding K, Whitehead M, Feld R, Murray N, Shepherd FA, et al. The impact of anemia on outcome of chemoradiation for limited small-cell lung cancer: a combined analysis of studies of the National Cancer Institute of Canada Clinical Trials Group. Ann Oncol. 2007;18(6):1051–5. doi:10.1093/annonc/mdm077.CrossRefPubMed

16.

Onodera T, Goseki N, Kosaki G. Prognostic nutritional index in gastrointestinal surgery of malnourished cancer patients. Nihon Geka Gakkaishi Zasshi. 1984;85(9):1001–5.

17.

Landskron G, De la Fuente M, Thuwajit P, Thuwajit C, Hermoso MA. Chronic inflammation and cytokines in the tumor microenvironment. J Immunol Res. 2014;2014:149185. doi:10.1155/2014/149185.CrossRefPubMedPubMedCentral

18.

Ikeya T, Shibutani M, Maeda K, Sugano K, Nagahara H, Ohtani H, et al. Maintenance of the nutritional prognostic index predicts survival in patients with unresectable metastatic colorectal cancer. J Cancer Res Clin Oncol. 2014. doi:10.1007/s00432-014-1799-8.PubMed

19.

Migita K, Takayama T, Saeki K, Matsumoto S, Wakatsuki K, Enomoto K, et al. The prognostic nutritional index predicts long-term outcomes of gastric cancer patients independent of tumor stage. Ann Surg Oncol. 2013;20(8):2647–54. doi:10.1245/s10434-013-2926-5.CrossRefPubMed

20.

Yao ZH, Tian GY, Wan YY, Kang YM, Guo HS, Liu QH, et al. Prognostic nutritional index predicts outcomes of malignant pleural mesothelioma. J Cancer Res Clin Oncol. 2013;139(12):2117–23. doi:10.1007/s00432-013-1523-0.CrossRefPubMed

21.

Pinato DJ, North BV, Sharma R. A novel, externally validated inflammation-based prognostic algorithm in hepatocellular carcinoma: the prognostic nutritional index (PNI). Br J Cancer. 2012;106(8):1439–45. doi:10.1038/bjc.2012.92.CrossRefPubMedPubMedCentral

22.

Wang DS, Luo HY, Qiu MZ, Wang ZQ, Zhang DS, Wang FH, et al. Comparison of the prognostic values of various inflammation based factors in patients with pancreatic cancer. Med Oncol. 2012;29(5):3092–100. doi:10.1007/s12032-012-0226-8.CrossRefPubMed

23.

van Meerbeeck JP, Fennell DA, De Ruysscher DK. Small-cell lung cancer. Lancet. 2011;378(9804):1741–55. doi:10.1016/S0140-6736(11)60165-7.CrossRefPubMed

24.

Budczies J, Klauschen F, Sinn BV, Gyorffy B, Schmitt WD, Darb-Esfahani S, et al. Cutoff Finder: a comprehensive and straightforward Web application enabling rapid biomarker cutoff optimization. PLoS One. 2012;7(12):e51862. doi:10.1371/journal.pone.0051862.CrossRefPubMedPubMedCentral

25.

Eatrides J, Thompson Z, Lee JH, Bello C, Dalia S. Serum albumin as a stable predictor of prognosis during initial treatment in patients with diffuse large B cell lymphoma. Ann Hematol. 2014. doi:10.1007/s00277-014-2150-9.PubMed

26.

Biswas B, Rastogi S, Khan SA, Shukla NK, Deo SV, Agarwala S, et al. Hypoalbuminaemia is an independent predictor of poor outcome in metastatic ewing’s sarcoma family of tumours: a single institutional experience of 150 cases treated with uniform chemotherapy protocol. Clin Oncol (R Coll Radiol). 2014. doi:10.1016/j.clon.2014.05.006.

27.

Du XJ, Tang LL, Mao YP, Sun Y, Zeng MS, Kang TB, et al. The pretreatment albumin to globulin ratio has predictive value for long-term mortality in nasopharyngeal carcinoma. PLoS One. 2014;9(4):e94473. doi:10.1371/journal.pone.0094473.CrossRefPubMedPubMedCentral

28.

Li G, Gao J, Liu ZG, Tao YL, Xu BQ, Tu ZW, et al. Influence of pretreatment ideal body weight percentile and albumin on prognosis of nasopharyngeal carcinoma: long-term outcomes of 512 patients from a single institution. Head Neck. 2014;36(5):660–6. doi:10.1002/hed.23357.CrossRefPubMed

29.

Douglas E, McMillan DC. Towards a simple objective framework for the investigation and treatment of cancer cachexia: the Glasgow Prognostic Score. Cancer Treat Rev. 2014;40(6):685–91. doi:10.1016/j.ctrv.2013.11.007.CrossRefPubMed

30.

McMillan DC. An inflammation-based prognostic score and its role in the nutrition-based management of patients with cancer. Proc Nutr Soc. 2008;67(3):257–62. doi:10.1017/S0029665108007131.CrossRefPubMed

31.

Templeton AJ, McNamara MG, Seruga B, Vera-Badillo FE, Aneja P, Ocana A, et al. Prognostic role of neutrophil-to-lymphocyte ratio in solid tumors: a systematic review and meta-analysis. J Natl Cancer Inst. 2014;106(6):dju124. doi:10.1093/jnci/dju124.CrossRefPubMed

32.

Templeton AJ, Ace O, McNamara MG, Al-Mubarak M, Vera-Badillo FE, Hermanns T, et al. Prognostic role of platelet to lymphocyte ratio in solid tumors: a systematic review and meta-analysis. Cancer Epidemiol Biomarkers Prev. 2014;23(7):1204–12. doi:10.1158/1055-9965.EPI-14-0146.CrossRefPubMed

33.

McMillan DC. The systemic inflammation-based Glasgow Prognostic Score: a decade of experience in patients with cancer. Cancer Treat Rev. 2013;39(5):534–40. doi:10.1016/j.ctrv.2012.08.003.CrossRefPubMed

34.

Rothschild MA, Oratz M, Schreiber SS. Serum albumin. Hepatology. 1988;8(2):385–401.CrossRefPubMed

35.

Mantovani A, Allavena P, Sica A, Balkwill F. Cancer-related inflammation. Nature. 2008;454(7203):436–44. doi:10.1038/nature07205.CrossRefPubMed

36.

Coussens LM, Werb Z. Inflammation and cancer. Nature. 2002;420(6917):860–7. doi:10.1038/nature01322.CrossRefPubMedPubMedCentral

37.

Ceze N, Thibault G, Goujon G, Viguier J, Watier H, Dorval E, et al. Pre-treatment lymphopenia as a prognostic biomarker in colorectal cancer patients receiving chemotherapy. Cancer Chemother Pharmacol. 2011;68(5):1305–13. doi:10.1007/s00280-011-1610-3.CrossRefPubMed

38.

Ray-Coquard I, Cropet C, Van Glabbeke M, Sebban C, Le Cesne A, Judson I, et al. Lymphopenia as a prognostic factor for overall survival in advanced carcinomas, sarcomas, and lymphomas. Cancer Res. 2009;69(13):5383–91. doi:10.1158/0008-5472.CAN-08-3845.CrossRefPubMedPubMedCentral

39.

Charles KA, Rivory LP, Brown SL, Liddle C, Clarke SJ, Robertson GR. Transcriptional repression of hepatic cytochrome P450 3A4 gene in the presence of cancer. Clin Cancer Res. 2006;12(24):7492–7. doi:10.1158/1078-0432.CCR-06-0023.CrossRefPubMed

40.

Rivory LP, Slaviero KA, Clarke SJ. Hepatic cytochrome P450 3A drug metabolism is reduced in cancer patients who have an acute-phase response. Br J Cancer. 2002;87(3):277–80. doi:10.1038/sj.bjc.6600448.CrossRefPubMedPubMedCentral

41.

Paccagnella A, Morassutti I, Rosti G. Nutritional intervention for improving treatment tolerance in cancer patients. Curr Opin Oncol. 2011;23(4):322–30. doi:10.1097/CCO.0b013e3283479c66.CrossRefPubMed

Title: The prognostic nutritional index (PNI) predicts overall survival of small-cell lung cancer patients
Authors: Shaodong Hong
Ting Zhou
Wenfeng Fang
Cong Xue
Zhihuang Hu
Tao Qin
Yanna Tang
Yue Chen
Yuxiang Ma
Yunpeng Yang
Xue Hou
Yan Huang
Hongyun Zhao
Yuanyuan Zhao
Li Zhang
Publication date: 01-05-2015
Publisher: Springer Netherlands
Published in: Tumor Biology / Issue 5/2015
Print ISSN: 1010-4283
Electronic ISSN: 1423-0380
DOI: https://doi.org/10.1007/s13277-014-2973-y

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 5/2015

Effect of HOTAIR rs920778 polymorphism on breast cancer susceptibility and clinicopathologic features in a Turkish population

IL-6 polymorphism in non-small cell lung cancer: a prognostic value?

Association between the genetic variations within TBX21 gene promoter and the clinicopathological characteristics of esophageal squamous cell carcinoma in a high-risk Chinese population

Association between six genetic variants of IL-17A and IL-17F and cervical cancer risk: a case–control study

Protein interactions of cortactin in relation to invadopodia formation in metastatic renal clear cell carcinoma

Letter regarding Li JS et al. entitled “ERCC polymorphisms and prognosis of patients with osteosarcoma”

Keynote webinar | Spotlight on antibody–drug conjugates in cancer